$6.02
Value $352M
EMBC and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$6.02
Value $352M
$339.85
Value $308B
Embecta (EMBC) has a market value of $352M and UnitedHealth (UNH) $308B. Over the last year, with dividends, EMBC moved -56.0% and UNH +12.9%. The P/E is 4.0 for EMBC and 19.4 for UNH. Dividend yield: EMBC 5.32%, UNH 2.67%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EMBC$352M
UNH$308B
UNH is 876 times EMBC
Revenue, 12 months
EMBC$1.0B
UNH$450B
UNH is 441 times EMBC
Net income, 12 months
EMBC$88M
UNH$15.9B
UNH is 182 times EMBC
Operating margin
EMBC21.9%
UNH5.3%
16.6 points apart
ROIC
EMBC20.4%
UNH11.3%
9.1 points apart
P/E
EMBC4.0
UNH19.4
UNH is 4.8 times EMBC
Dividend yield
EMBC5.3%
UNH2.7%
2.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EMBC-58.6%
UNH-32.4%
| Period | EMBCWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -56.0%Price -57.4% | +12.9%Price +10.0% |
| 3 years since November 20, 2023 | -58.6%-25.5% a yearPrice -63.1% | -32.4%-12.2% a yearPrice -36.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
EMBCEmbectaUNHUnitedHealth
| Price | $6.02 | $339.85 |
|---|---|---|
| Market value | $352M | $308B |
| Enterprise value (EV) | $1.6B | $354B |
| P/E | 4.0 | 19.4 |
| P/E, 5-year median | 9.6 | 25.0 |
| P/B | – | 3.0 |
| EV/EBIT | 7.3 | 14.8 |
| Free cash flow yield | 46.7% | 7.4% |
| Revenue, 12 months | $1.0B | $450B |
|---|---|---|
| Net income, 12 months | $88M | $15.9B |
| Free cash flow, 12 months | $165M | $22.8B |
| Earnings per share, 12 months | $1.47 | $17.52 |
| Revenue growth, year on year | -3.8% | 11.8% |
| Revenue growth a year, past | -0.1%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | -26.4%over 5 years | -3.8%over 5 years |
| Gross margin | 59.0% | 88.3% |
|---|---|---|
| Operating margin | 21.9% | 5.3% |
| Net margin | 8.6% | 3.5% |
| ROIC | 20.4% | 11.3% |
| ROE | – | 15.5% |
| Cash | $215M | $28.5B |
|---|---|---|
| Total debt | $1.5B | $74.3B |
| Net debt / EBITDA | 4.8 | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | 5.3% | 2.7% |
|---|---|---|
| Dividend per share, 12 months | $0.32 | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | 5.3% | 4.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($308B) is about 875.7 times Embecta ($352M), at today's prices.
Since November 20, 2023, EMBC's price moved -63.1% and UNH's -36.5%. With dividends: EMBC -58.6% (-25.5% a year), UNH -32.4% (-12.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 5.32% for Embecta and 2.67% for UnitedHealth. Over the last twelve months they paid $0.32 and $9.06 per share.
At today's price, the P/E is 4.0 for EMBC and 19.4 for UNH. The median of the last five years was 9.6 and 25.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 8.6% for Embecta and 3.5% for UnitedHealth, and the operating margin 21.9% and 5.3%. Revenue was $1.0B and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.